MODIFIED IMMUNOGENIC PEPTIDE AGAINST STREPTOCOCCUS A
- Summary
- An immunogenic peptide for prevention and treatment of group A streptococcus streptococcus-associated diseases and conditions
- Technology Benefits
- Vaccine to prevent group A streptococci infection
- Technology Application
- Vaccine - disease prevention
- Detailed Technology Description
- The present inventors have discovered that the immunogenicity of a p145 peptide can be substantially increased by targeted modification of the amino acid sequence of p145. A single immunization with the modified p145 peptide, rather than multiple immunizations, can protect against group A streptococcus infection even by hypervirulent strains such as the CovR/S mutant strain.
- Type of Cooperation
- Licensing
- Application Date
- 23/08/2017 00:00:00
- Application No.
- 2019439
- Country/Region
- Netherlands
For more information, please click Here
